An immune phenotype has also been associated with benefit from immunotherapy with the newest agents targeting inhibitory immune checkpoint molecules that are advancing the treatment of several aggressive neoplastic diseases. In genito-urinary tumors, their use has been associated with a clear benefit in advanced urothelial bladder cancer and kidney cancer and currently several trials are ongoing on early stages of the diseases.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Our review focused on the role of TILs in prostate, bladder and testicular cancers. Most of the evidence came from retrospective studies and few prospective trials ongoing. Therefore, further investigations are needed to clarify whether the assessment of TILs would have a prognostic and/or predictive significance in these specific diseases.
In addition to TILs, there are many molecular factors which are also under investigation as prognostic and/or predictive factors. PD-L1 expression, immune gene signature, IL-8 and mutation burden are among these factors. A combination of several factors (immunogram) might be more pertinent than individual parameter and this approach is under investigation.
Written By: Cinzia Solinas, MD, Molecular Immunology Unit, Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium; Nieves Martinez Chanzá, Medical Oncology, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium; Ahmad Awada, MD, PhD, Medical Oncology, Université Libre de Bruxelles, Institut Jules Bordet; Mario Scartozzi, MD, PhD, Medical Oncology, University of Cagliari, Cagliari, Italy
Read the Abstract